Get started
Author

Ryusuke Hayashi

Observed name: Hayashi, Ryusuke
ORCID: 0000-0002-9868-2286
Observed ORCID: 0000-0002-9868-2286
OpenAlex ID: A5043393928
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes
2021 · Akemi Kosaka, Kei Ishibashi, et al. · The Journal of Experimental Medicine · 58
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
2022 · Michihisa Kono, Hiroki Komatsuda, et al. · OncoImmunology · 38
A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment
2021 · Marino Nagata, Akemi Kosaka, et al. · Cancer Immunology Immunotherapy · 32
Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma
2019 · Shohei Harabuchi, Akemi Kosaka, et al. · Biochemical and Biophysical Research Communications · 28
PDF
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer
2020 · Mizuho Ohara, Kenzo Ohara, et al. · Cancer Immunology Immunotherapy · 24
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma
2020 · Ryusuke Hayashi, Toshihiro Nagato, et al. · OncoImmunology · 21
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery
2021 · Michihisa Kono, Takumi Kumai, et al. · Cancer Immunology Immunotherapy · 20
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma
2019 · Toshihiro Nagato, Seigo Ueda, et al. · Laboratory Investigation · 18
PDF
Cholinergic sensing of allergen exposure by airway epithelium promotes type 2 immunity in the lungs
2023 · Ryusuke Hayashi, Yotesawee Srisomboon, et al. · Journal of Allergy and Clinical Immunology · 17
PDF
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy
2021 · Akemi Kosaka, Yuki Yajima, et al. · Cancer Science · 12
PDF
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer
2023 · Hidekiyo Yamaki, Michihisa Kono, et al. · Cancer Immunology Immunotherapy · 8
PDF
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy
2023 · Toshihiro Nagato, Hiroki Komatsuda, et al. · Cancer Immunology Immunotherapy · 8
PDF
The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer
2021 · Satoshi Okazaki, Takaaki Sasaki, et al. · Oncology Letters · 8
PDF
Immunotherapy targeting tumor‐associated antigen in a mouse model of head and neck cancer
2024 · Michihisa Kono, Risa Wakisaka, et al. · Head & Neck · 5
PDF
Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy
2026 · Ryosuke Sato, Shota Sakaue, et al. · Cancer Immunology Immunotherapy
Data from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 4 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 4 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Table 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 3 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 3 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Works count: 34
Citation count: 297
H-index: 10
I10-index: 10
Year
Topic
Type